Tim Allsopp

Company: Laverock Therapeutics

Job title: Chief Technology Officer

Seminars:

Considering Stealth Approaches for Allogeneic Therapies to Avoid Immune System Detection 10:00 am

• Exploring use of siRNA, shRNA, and microRNA to silence immunogenic signalling in allogeneic T-cells • Understanding the benefits awarded to patients by optimising • Potency vs stealth: evaluating prioritisation of therapy characteristic dependent on disease type and severityRead more

day: Day One